{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:27:22Z","timestamp":1791606442876,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["E76D17000080009"],"award-info":[{"award-number":["E76D17000080009"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      In the search of genetic determinants of Duchenne muscular dystrophy (DMD) severity,\n                      <jats:italic>LTBP4<\/jats:italic>\n                      , a member of the latent TGF-\u03b2 binding protein family, emerged as an important predictor of functional outcome trajectories in mice and humans. Nonsynonymous single-nucleotide polymorphisms in\n                      <jats:italic>LTBP4<\/jats:italic>\n                      gene associate with prolonged ambulation in DMD patients, whereas an in-frame insertion polymorphism in the mouse\n                      <jats:italic>LTBP4<\/jats:italic>\n                      locus modulates disease severity in mice by altering proteolytic stability of the Ltbp4 protein and release of transforming growth factor-\u03b2 (TGF-\u03b2). Givinostat, a pan-histone deacetylase inhibitor currently in phase III clinical trials for DMD treatment, significantly reduces fibrosis in muscle tissue and promotes the increase of the cross-sectional area (CSA) of muscles in\n                      <jats:italic>mdx<\/jats:italic>\n                      mice. In this study, we investigated the activity of Givinostat in\n                      <jats:italic>mdx<\/jats:italic>\n                      and in D2.B10 mice, two mouse models expressing different Ltbp4 variants and developing mild or more severe disease as a function of Ltbp4 polymorphism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Givinostat and steroids were administrated for 15\u2009weeks in both DMD murine models and their efficacy was evaluated by grip strength and run to exhaustion functional tests. Histological examinations of skeletal muscles were also performed to assess the percentage of fibrotic area and CSA increase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Givinostat treatment increased maximal normalized strength to levels that were comparable to those of healthy mice in both DMD models. The effect of Givinostat in both grip strength and exhaustion tests was dose-dependent in both strains, and in D2.B10 mice, Givinostat outperformed steroids at its highest dose. The in vivo treatment with Givinostat was effective in improving muscle morphology in both\n                      <jats:italic>mdx<\/jats:italic>\n                      and D2.B10 mice by reducing fibrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our study provides evidence that Givinostat has a significant effect in ameliorating both muscle function and histological parameters in\n                      <jats:italic>mdx<\/jats:italic>\n                      and D2.B10 murine models suggesting a potential benefit also for patients with a poor prognosis\n                      <jats:italic>LTBP4<\/jats:italic>\n                      genotype.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13395-021-00273-6","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T02:02:51Z","timestamp":1626919371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7597-7084","authenticated-orcid":false,"given":"Simonetta Andrea","family":"Licandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pomarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Perego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steink\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"issue":"3","key":"273_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014;32(3):671\u201388. https:\/\/doi.org\/10.1016\/j.ncl.2014.05.002.","journal-title":"Neurol Clin."},{"issue":"4","key":"273_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JND-170280","volume":"4","author":"Z Koeks","year":"2017","unstructured":"Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, et al. Clinical outcomes in Duchenne muscular dystrophy: a study of 5345 patients from the TREAT-NMD DMD Global Database. J Neuromuscul Dis. 2017;4(4):293\u2013306. https:\/\/doi.org\/10.3233\/JND-170280.","journal-title":"J Neuromuscul Dis."},{"issue":"5","key":"273_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11940-014-0287-4","volume":"16","author":"N Goemans","year":"2014","unstructured":"Goemans N, Buyse G. Current treatment and management of dystrophinopathies. Curr Treat Options Neurol. 2014;16(5):287. https:\/\/doi.org\/10.1007\/s11940-014-0287-4.","journal-title":"Curr Treat Options Neurol."},{"issue":"17","key":"273_CR4","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY. Eteplirsen: first global approval. Drugs. 2016;76(17):1699\u2013704. Review. https:\/\/doi.org\/10.1007\/s40265-016-0657-1.","journal-title":"Drugs."},{"issue":"3","key":"273_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph13030040","volume":"13","author":"D Al Shaer","year":"2020","unstructured":"Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2019 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals (Basel). 2020;13(3):40. Review. https:\/\/doi.org\/10.3390\/ph13030040.","journal-title":"Pharmaceuticals (Basel)."},{"issue":"3","key":"273_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/jpm10030111","volume":"10","author":"O Sheikh","year":"2020","unstructured":"Sheikh O, Yokota T. Advances in genetic characterization and genotype-phenotype correlation of Duchenne and Becker muscular dystrophy in the personalized medicine era. J Pers Med. 2020;10(3):111. https:\/\/doi.org\/10.3390\/jpm10030111.","journal-title":"J Pers Med."},{"issue":"4","key":"273_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477\u201387. https:\/\/doi.org\/10.1002\/mus.24332.","journal-title":"Muscle Nerve."},{"issue":"14","key":"273_CR8","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","volume":"74","author":"NJ Ryan","year":"2014","unstructured":"Ryan NJ. Ataluren: first global approval. Drugs. 2014;74(14) Review:1709\u201314. https:\/\/doi.org\/10.1007\/s40265-014-0287-4.","journal-title":"Drugs."},{"issue":"12","key":"273_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048\u201355. https:\/\/doi.org\/10.1212\/WNL.0000000000001950.","journal-title":"Neurology."},{"issue":"10119","key":"273_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne Muscular Dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(17)32160-8.","journal-title":"Lancet."},{"issue":"8","key":"273_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/1060028019900500","volume":"54","author":"M Bylo","year":"2020","unstructured":"Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A review of Deflazacort for patients with Duchenne muscular dystrophy. Ann Pharmacother. 2020;54(8):788\u201394. Review. https:\/\/doi.org\/10.1177\/1060028019900500.","journal-title":"Ann Pharmacother."},{"key":"273_CR12","volume":"5","author":"E Matthews","year":"2016","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;5:CD003725.","journal-title":"Cochrane Database Syst Rev."},{"key":"273_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jpeds.2016.11.078","volume":"182","author":"BL Wong","year":"2017","unstructured":"Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, et al. Long-term outcome of interdisciplinary management of patients with Duchenne muscular dystrophy receiving daily glucocorticoid treatment. J Pediatr. 2017;182:296\u2013303 e1.","journal-title":"J Pediatr"},{"issue":"4","key":"273_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034204","volume":"7","author":"A Sali","year":"2012","unstructured":"Sali A, Guerron AD, Gordish-Dressman H, Spurney CF, Iantorno M, Hoffman EP, et al. Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mice. Plos One. 2012;7(4):e34204. https:\/\/doi.org\/10.1371\/journal.pone.0034204.","journal-title":"Plos One"},{"issue":"6","key":"273_CR15","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1172\/JCI91445","volume":"127","author":"M Quattrocelli","year":"2017","unstructured":"Quattrocelli M, Barefield DY, Warner JL, Vo AH, Hadhazy M, Earley JU, et al. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. J Clin Invest. 2017;127(6):2418\u201332. https:\/\/doi.org\/10.1172\/JCI91445.","journal-title":"J Clin Invest."},{"issue":"12","key":"273_CR16","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1172\/JCI39845","volume":"119","author":"A Heydemann","year":"2009","unstructured":"Heydemann A, Ceco E, Lim JE, Hadhazy M, Ryder P, Moran JL, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest. 2009;119(12):3703\u201312. https:\/\/doi.org\/10.1172\/JCI39845.","journal-title":"J Clin Invest."},{"issue":"4","key":"273_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.23819","volume":"73","author":"KM Flanigan","year":"2013","unstructured":"Flanigan KM, Ceco E, Lamar KM, Kaminoh Y, Dunn DM, Mendell JR, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol. 2013;73(4):481\u20138. https:\/\/doi.org\/10.1002\/ana.23819.","journal-title":"Ann Neurol"},{"issue":"1","key":"273_CR18","doi-asserted-by":"publisher","first-page":"14070","DOI":"10.1038\/s41598-020-70987-y","volume":"10","author":"DW Hammers","year":"2020","unstructured":"Hammers DW, Hart CC, Matheny MK, Wright LA, Armellini M, Barton ER, et al. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy. Sci Rep. 2020;10(1):14070.","journal-title":"Sci Rep"},{"issue":"259","key":"273_CR19","doi-asserted-by":"publisher","first-page":"259ra144","DOI":"10.1126\/scitranslmed.3010018","volume":"6","author":"E Ceco","year":"2014","unstructured":"Ceco E, Bogdanovich S, Gardner B, Miller T, DeJesus A, Earley JU, et al. Targeting latent TGF\u03b2 release in muscular dystrophy. Sci Transl Med. 2014;6(259):259ra144.","journal-title":"Sci Transl Med"},{"issue":"5","key":"273_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/labinvest.2017.20","volume":"97","author":"J Lu","year":"2017","unstructured":"Lu J, Liu Q, Wang L, Tu W, Chu H, Ding W, et al. Increased expression of latent TGF-beta-binding protein 4 affects the fibrotic process in scleroderma by TGF-beta\/SMAD signaling. Lab Invest. 2017;97(5):591\u2013601. https:\/\/doi.org\/10.1038\/labinvest.2017.20.","journal-title":"Lab Invest."},{"issue":"2","key":"273_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI118101","volume":"96","author":"P Bernasconi","year":"1995","unstructured":"Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J. Clin. Invest. 1995;96(2):1137\u201344. https:\/\/doi.org\/10.1172\/JCI118101.","journal-title":"J. Clin. Invest."},{"issue":"4","key":"273_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ana.24370","volume":"77","author":"L Bello","year":"2015","unstructured":"Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, et al. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study. Ann Neurol. 2015;77(4):684\u201396. https:\/\/doi.org\/10.1002\/ana.24370.","journal-title":"Ann Neurol."},{"issue":"10","key":"273_CR23","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/jnnp-2014-308409","volume":"86","author":"JC Van den Bergen","year":"2015","unstructured":"Van den Bergen JC, Hiller M, B\u00f6hringer S, Vijfhuizen L, Ginjaar HB, Chaouch A, et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry. 2015;86(10):1060\u20135. https:\/\/doi.org\/10.1136\/jnnp-2014-308409.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"273_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada SI, Yokota T. Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscul Dis. 2016;3(1):29\u201348. Review. https:\/\/doi.org\/10.3233\/JND-150113.","journal-title":"J Neuromuscul Dis."},{"issue":"5","key":"273_CR25","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.2353\/ajpath.2010.090887","volume":"176","author":"S Fukada","year":"2010","unstructured":"Fukada S, Morikawa D, Yamamoto Y, Yoshida T, Sumie N, Yamaguchi M, et al. Genetic background affects properties of satellite cells and mdx phenotypes. Am J Pathol. 2010;176(5):2414\u201324. https:\/\/doi.org\/10.2353\/ajpath.2010.090887.","journal-title":"Am J Pathol."},{"issue":"1","key":"273_CR26","doi-asserted-by":"publisher","first-page":"38371","DOI":"10.1038\/srep38371","volume":"6","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Maruyama R, Lim KRQ, Fukada SI, Yokota T. Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient Mdx muscles on DBA\/2 background. Sci Rep. 2016;6(1):38371. https:\/\/doi.org\/10.1038\/srep38371.","journal-title":"Sci Rep."},{"issue":"10","key":"273_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nm1479","volume":"12","author":"GC Minetti","year":"2006","unstructured":"Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006;12(10):1147\u201350. https:\/\/doi.org\/10.1038\/nm1479.","journal-title":"Nat Med"},{"issue":"49","key":"273_CR28","doi-asserted-by":"publisher","first-page":"19183","DOI":"10.1073\/pnas.0805514105","volume":"105","author":"C Colussi","year":"2008","unstructured":"Colussi C, Mozzetta C, Gurtner A, Illi B, Rosati J, Straino S, et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA. 2008;105(49):19183\u20137. https:\/\/doi.org\/10.1073\/pnas.0805514105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"273_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/prca.200900116","volume":"4","author":"C Colussi","year":"2010","unstructured":"Colussi C, Brioschi M, Tremoli E, Straino S, Spallotta F, Mai A, et al. Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics Clin Appl. 2010;4(1):71\u201383. https:\/\/doi.org\/10.1002\/prca.200900116.","journal-title":"Proteomics Clin Appl."},{"issue":"1","key":"273_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2119\/molmed.2013.00011","volume":"19","author":"S Consalvi","year":"2013","unstructured":"Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, et al. Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor Givinostat. Mol Med. 2013;19(1):79\u201387. https:\/\/doi.org\/10.2119\/molmed.2013.00011.","journal-title":"Mol Med."},{"issue":"10","key":"273_CR31","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D'Oria V, D'Amico A, Catteruccia M, Pane M, et al. Histological effects of Givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26(10):643\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2016.07.002.","journal-title":"Neuromuscul Disord."},{"issue":"1","key":"273_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddv460","volume":"25","author":"WD Coley","year":"2016","unstructured":"Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, et al. Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet. 2016;25(1):130\u201345. https:\/\/doi.org\/10.1093\/hmg\/ddv460.","journal-title":"Hum Mol Genet."},{"key":"273_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bcp.2018.04.022","volume":"154","author":"P Mantuano","year":"2018","unstructured":"Mantuano P, Sanarica F, Conte E, Morgese MG, Capogrosso RF, Cozzoli A, et al. Effect of a long-term treatment with metformin in dystrophic mdx mice: a reconsideration of its potential clinical interest in Duchenne muscular dystrophy. Biochem Pharmacol. 2018;154:89\u2013103. https:\/\/doi.org\/10.1016\/j.bcp.2018.04.022.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"273_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1023\/A:1020884312053","volume":"32","author":"AA Bachmanov","year":"2002","unstructured":"Bachmanov AA, Reed DR, Beauchamp GK, Tordoff MG. Food intake, water intake, and drinking spout side preference of 28 mouse strains. Behav Genet. 2002;32(6):435\u201343. https:\/\/doi.org\/10.1023\/A:1020884312053.","journal-title":"Behav Genet."},{"key":"273_CR35","unstructured":"De Luca A. Use of grip strength meter to assess the limb strength of mdx mice. In: Experimental protocols for DMD animal models. Treat-NMD Neuromuscular Network. 2019. https:\/\/treat-nmd.org\/wp-content\/uploads\/2016\/08\/MDX-DMD_M.2.2.001.pdf. Accessed 3 September 2008."},{"key":"273_CR36","unstructured":"Grange RW. Use of treadmill and wheel exercise to assess dystrophic state. In: Experimental protocols for DMD animal models. Treat-NMD Neuromuscular Network. 2015. https:\/\/treat-nmd.org\/wp-content\/uploads\/2016\/08\/MDX-DMD_M.2.1.003-34.pdf. Accessed 12 November 2008."},{"issue":"4","key":"273_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407\u201384. https:\/\/doi.org\/10.1177\/074823379701300401.","journal-title":"Toxicol Ind Health"},{"issue":"3","key":"273_CR38","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25. https:\/\/doi.org\/10.1186\/gb-2009-10-3-r25.","journal-title":"Genome Biol."},{"issue":"4","key":"273_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.0006-341X.2003.00130.x","volume":"59","author":"L Wouters","year":"2003","unstructured":"Wouters L, G\u00f6hlmann HW, Bijnens L, Kass SU, Molenberghs G, Lewi PJ. Graphical exploration of gene expression data: a comparative study of three multivariate methods. Biometrics. 2003;59(4):1131\u20139. https:\/\/doi.org\/10.1111\/j.0006-341X.2003.00130.x.","journal-title":"Biometrics."},{"issue":"12","key":"273_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol."},{"issue":"21","key":"273_CR41","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.1073\/pnas.0914005107","volume":"107","author":"R Bourgon","year":"2010","unstructured":"Bourgon R, Gentleman R, Huber W. Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci U S A. 2010;107(21):9546\u201351. https:\/\/doi.org\/10.1073\/pnas.0914005107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"273_CR42","doi-asserted-by":"publisher","DOI":"10.4161\/21675511.2014.974969","volume":"2","author":"L Giordani","year":"2014","unstructured":"Giordani L, Sandon\u00e1 M, Rotini A, Puri PL, Consalvi S, Saccone V. Muscle-specific microRNAs as biomarkers of Duchenne muscular dystrophy progression and response to therapies. Rare Dis. 2014;2(1):e974969. https:\/\/doi.org\/10.4161\/21675511.2014.974969.","journal-title":"Rare Dis."},{"issue":"6","key":"273_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12199-014-0405-7","volume":"19","author":"Y Matsuzaka","year":"2014","unstructured":"Matsuzaka Y, Kishi S, Aoki Y, Komaki H, Oya Y, Takeda S, et al. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy. Environ Health Prev Med. 2014;19(6):452\u20138. https:\/\/doi.org\/10.1007\/s12199-014-0405-7.","journal-title":"Environ Health Prev Med."},{"issue":"R1","key":"273_CR44","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1093\/hmg\/dds317","volume":"21","author":"Y Lee","year":"2012","unstructured":"Lee Y, Andaloussi SE, Wood MJA. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21(R1):R125\u201334. https:\/\/doi.org\/10.1093\/hmg\/dds317.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"273_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/cdd.2014.130","volume":"22","author":"C Braicu","year":"2015","unstructured":"Braicu C, Tomuleasa C, Monroig P, Cucuianu A, Berindan-Neagoe I, Calin GA. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015;22(1):34\u201345. https:\/\/doi.org\/10.1038\/cdd.2014.130.","journal-title":"Cell Death Differ."},{"issue":"2","key":"273_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms17020171","volume":"17","author":"N Iraci","year":"2016","unstructured":"Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci. 2016;17(2):171. https:\/\/doi.org\/10.3390\/ijms17020171.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"273_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018388","volume":"6","author":"H Mizuno","year":"2011","unstructured":"Mizuno H, Nakamura A, Aoki Y, Ito N, Kishi S, Yamamoto K, et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One. 2011;6(3):e18388. https:\/\/doi.org\/10.1371\/journal.pone.0018388.","journal-title":"PLoS One."},{"key":"273_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2018.08.005","volume":"13","author":"AML Coenen-Stass","year":"2018","unstructured":"Coenen-Stass AML, Sork H, Gatto S, Godfrey C, Bhomra A, Krjut\u0161kov K, et al. Comprehensive RNA-sequencing analysis in serum and muscle reveals novel small RNA signatures with biomarker potential for DMD. Mol Ther Nucleic Acids. 2018;13:1\u201315. https:\/\/doi.org\/10.1016\/j.omtn.2018.08.005.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"5","key":"273_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/emmm.201100133","volume":"3","author":"D Cacchiarelli","year":"2011","unstructured":"Cacchiarelli D, Legnini I, Martone J, Cazzella V, D\u2019Amico A, Bertini E, et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med. 2011;3(5):258\u201365. https:\/\/doi.org\/10.1002\/emmm.201100133.","journal-title":"EMBO Mol Med."},{"issue":"2","key":"273_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ng1725","volume":"38","author":"JF Chen","year":"2006","unstructured":"Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38(2):228\u201333. https:\/\/doi.org\/10.1038\/ng1725.","journal-title":"Nat Genet."},{"issue":"1","key":"273_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-213X-11-34","volume":"11","author":"A Koutsoulidou","year":"2011","unstructured":"Koutsoulidou A, Mastroyiannopoulos NP, Furling D, Uney JB, Phylactou LA. Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle. BMC Dev Biol. 2011;11(1):34. https:\/\/doi.org\/10.1186\/1471-213X-11-34.","journal-title":"BMC Dev Biol."},{"issue":"2","key":"273_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1247\/csf.08022","volume":"33","author":"K Yuasa","year":"2008","unstructured":"Yuasa K, Hagiwara Y, Ando M, Nakamura A, Takeda S, Hijikata T. MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. Cell Struct Funct. 2008;33(2):163\u20139. https:\/\/doi.org\/10.1247\/csf.08022.","journal-title":"Cell Struct Funct."},{"issue":"6","key":"273_CR53","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1172\/JCI62656","volume":"122","author":"N Liu","year":"2012","unstructured":"Liu N, Williams AH, Maxeiner JM, Bezprozvannaya S, Shelton JM, Richardson JA, et al. microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J Clin Invest. 2012;122(6):2054\u201365. https:\/\/doi.org\/10.1172\/JCI62656.","journal-title":"J Clin Invest."},{"issue":"20","key":"273_CR54","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1093\/nar\/gkt724","volume":"41","author":"TC Roberts","year":"2013","unstructured":"Roberts TC, Godfrey C, McClorey G, Vader P, Briggs D, Gardiner C, et al. Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover. Nucleic Acids Res. 2013;41(20):9500\u201313. https:\/\/doi.org\/10.1093\/nar\/gkt724.","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"273_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141138","volume":"10","author":"Z Wang","year":"2015","unstructured":"Wang Z, Li Q, Chamba Y, Zhang B, Shang P, Zhang H, et al. Identification of genes related to growth and lipid deposition from transcriptome profiles of pig muscle tissue. PLoS One. 2015;10(10):e0141138. https:\/\/doi.org\/10.1371\/journal.pone.0141138.","journal-title":"PLoS One."},{"issue":"8","key":"273_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1101\/gad.234468.113","volume":"28","author":"V Saccone","year":"2014","unstructured":"Saccone V, Consalvi S, Giordani L, Mozzetta C, Barozzi I, Sandon\u00e1 M, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. Genes Dev. 2014;28(8):841\u201357. https:\/\/doi.org\/10.1101\/gad.234468.113.","journal-title":"Genes Dev."},{"issue":"9","key":"273_CR57","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202050863","volume":"21","author":"M Sandon\u00e0","year":"2020","unstructured":"Sandon\u00e0 M, Consalvi S, Tucciarone L, De Bardi M, Scimeca M, Angelini D, et al. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells. EMBO Rep. 2020;21(9):e50863. https:\/\/doi.org\/10.15252\/embr.202050863.","journal-title":"EMBO Rep."},{"issue":"3","key":"273_CR58","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/ehf2.12597","volume":"7","author":"I Ben-Zvi","year":"2020","unstructured":"Ben-Zvi I, Volinsky N, Grosman-Rimon L, Haviv I, Rozen G, Andria N, et al. Cardiac-peripheral transvenous gradients of microRNA expression in systolic heart failure patients. ESC Heart Fail. 2020;7(3):835\u201343. https:\/\/doi.org\/10.1002\/ehf2.12597.","journal-title":"ESC Heart Fail."},{"issue":"54","key":"273_CR59","doi-asserted-by":"publisher","first-page":"92079","DOI":"10.18632\/oncotarget.20759","volume":"8","author":"ZQ Hu","year":"2017","unstructured":"Hu ZQ, Luo JF, Yu XJ, Zhu JN, Huang L, Yang J, et al. Targeting myocyte-specific enhancer factor 2D contributes to the suppression of cardiac hypertrophic growth by miR-92b-3p in mice. Oncotarget. 2017;8(54):92079\u201389. https:\/\/doi.org\/10.18632\/oncotarget.20759.","journal-title":"Oncotarget."},{"key":"273_CR60","doi-asserted-by":"publisher","first-page":"116635","DOI":"10.1016\/j.lfs.2019.116635","volume":"232","author":"XJ Yu","year":"2019","unstructured":"Yu XJ, Huang YQ, Shan ZX, Zhu JN, Hu ZQ, Huang L, et al. MicroRNA-92b-3p suppresses angiotensin II-induced cardiomyocyte hypertrophy via targeting HAND2. Life Sci. 2019;232:116635. https:\/\/doi.org\/10.1016\/j.lfs.2019.116635.","journal-title":"Life Sci."},{"issue":"10","key":"273_CR61","first-page":"742","volume":"71","author":"KM Jaffe","year":"1990","unstructured":"Jaffe KM, McDonald CM, Ingman E, Haas J. Symptoms of upper gastrointestinal dysfunction in Duchenne muscular dystrophy: case-control study. Arch Phys Med Rehabil. 1990;71(10):742\u20134.","journal-title":"Arch Phys Med Rehabil."},{"issue":"4","key":"273_CR62","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/emmm.201202096","volume":"5","author":"C Mozzetta","year":"2013","unstructured":"Mozzetta C, Consalvi S, Saccone V, Tierney M, Diamantini A, Mitchell KJ, et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old Mdx mice. EMBO Mol Med. 2013;5(4):626\u201339. https:\/\/doi.org\/10.1002\/emmm.201202096.","journal-title":"EMBO Mol Med."},{"issue":"427","key":"273_CR63","doi-asserted-by":"publisher","first-page":"eaao0144","DOI":"10.1126\/scitranslmed.aao0144","volume":"10","author":"MY Jeong","year":"2018","unstructured":"Jeong MY, Lin YH, Wennersten SA, Demos-Davies KM, Cavasin MA, Mahaffey JH, et al. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med. 2018;10(427):eaao0144.","journal-title":"Sci Transl Med"},{"issue":"4","key":"273_CR64","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2010.07.008","volume":"12","author":"D Cacchiarelli","year":"2010","unstructured":"Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, et al. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin\/nNOS pathway. Cell Metab. 2010;12(4):341\u201351. https:\/\/doi.org\/10.1016\/j.cmet.2010.07.008.","journal-title":"Cell Metab."},{"issue":"42","key":"273_CR65","doi-asserted-by":"publisher","first-page":"E2865","DOI":"10.1073\/pnas.1121131109","volume":"109","author":"X Chen","year":"2012","unstructured":"Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A. 2012;109(42):E2865\u201374. https:\/\/doi.org\/10.1073\/pnas.1121131109.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"273_CR66","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nchembio.313","volume":"6","author":"JE Bradner","year":"2010","unstructured":"Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238\u201343. https:\/\/doi.org\/10.1038\/nchembio.313.","journal-title":"Nat Chem Biol."},{"issue":"10","key":"273_CR67","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1124\/dmd.104.000638","volume":"32","author":"L Sanderson","year":"2004","unstructured":"Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, et al. Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos. 2004;32(10):1132\u20138. https:\/\/doi.org\/10.1124\/dmd.104.000638.","journal-title":"Drug Metab Dispos."},{"issue":"5","key":"273_CR68","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1073\/pnas.052702999","volume":"99","author":"F Leoni","year":"2002","unstructured":"Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A. 2002;99(5):2995\u20133000. https:\/\/doi.org\/10.1073\/pnas.052702999.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1-12","key":"273_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","volume":"11","author":"F Leoni","year":"2005","unstructured":"Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11(1-12):1\u201315. https:\/\/doi.org\/10.2119\/2006-00005.Dinarello.","journal-title":"Mol Med."},{"issue":"9","key":"273_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77(9):1\u201310.","journal-title":"JAMA Neurol."},{"issue":"5-6","key":"273_CR71","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2119\/molmed.2011.00049","volume":"17","author":"S Consalvi","year":"2011","unstructured":"Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol Med. 2011;17(5-6):457\u201365. https:\/\/doi.org\/10.2119\/molmed.2011.00049.","journal-title":"Mol Med."}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-021-00273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-021-00273-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-021-00273-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T14:04:07Z","timestamp":1626962647000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-021-00273-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1186\/s13395-021-00273-6","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mice were handled according to our Institutional Guidelines in compliance with national and international laws and policies (Italian Governing Law: D.lgs 26\/2014 \u201cAttuazione della direttiva 2010\/63\/UE sulla protezione degli animali utilizzati a fini scientifici\u201d). The research project has been authorized by the Italian Ministry of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SAL, FL, CS, R Pomarico, R Perego, and GF declare that they have financial competing interest as they are Italfarmaco\u2019s employees. LC declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}